Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Published Online: 2017-06-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: David Miles•Ian E Krop•Jin Xu•José Baselga•Kim Blackwell•Luca Gianni•Manfred Welslau•Marjorie Green•Mark Pegram•Silke Hoersch•Sunil Verma•Véronique Diéras
